BioVie Plans $70M Equity Offering; Positive PD Trial Results

BioVie Inc. filed an S-1 amendment for a "best efforts" public offering of up to 56,390,977 shares of Class A Common Stock and an equal number of Pre-Funded Warrants, aiming to raise approximately $70.0 million for general corporate purposes. The company also announced positive topline results from its Phase 2b SUNRISE-PD trial for Parkinson's disease, showing significant reduction in neuroinflammation and improved symptoms. However, its Phase 3 Alzheimer's trial was underpowered due to significant protocol deviations and cGCP violations at multiple study sites, leading to patient exclusions. The Phase 2 ADDRESS-LC study for Long COVID completed enrollment, with results expected in late summer 2026.